Naumann Foundation opens Human Rights Hub in Geneva / German Federal Minister of Justice Dr. Buschmann: "The brave need support."
(Geneva, Switzerland) – On July 10, the Friedrich Naumann Foundation for Freedom officially opens its Human Rights Hub in Geneva. The Human Rights Hub will be a hub for the promotion of freedom and human rights worldwide. Journalists, lawyers, activists - many are committed to the universal defense of human rights. In doing so, they often put their own freedom or lives at risk. Freedom is not free - it must be defended by liberal societies and single individuals. Dr. Michaela Lissowsky will serve as the hub’s director.
Anne Brasseur, former President of the Parliamentary Assembly of the Council of Europe and member of the Board of the Friedrich Naumann Foundation for Freedom:
"Geneva is the world capital of human rights and the rule of law. This is where people come together, network, become visible and have their voices heard. All over the world, people are threatened, imprisoned or tortured if they want to express their opinion, argue their case in court or report critically. Standing up for the universal application of human rights every day is at the heart of our mission as the Friedrich Naumann Foundation for Freedom. I am very pleased that the Human Rights Hub in Geneva will be such a place of encounter and joining forces."
The German Federal Minister of Justice, Dr. Marco Buschmann, who will inaugurate the Human Rights Hub in Geneva, congratulates with the following words:
"Human rights protect people. They protect the individual. At the same time, it is individuals who stand up and fight for these rights. It takes individuals with courage. Because without courage, it wouldn't have been possible to defend Alexander Navalny in court in Russia. Without courage, you can't fight corruption or help safeguard the rule of law in Zimbabwe. Without courage, you can't stand up to those who despise human rights. But even the courageous need help. The Human Rights Hub of the Friedrich Naumann Foundation for Freedom in Geneva will support them in finding that help, winning over fellow campaigners and generating attention. I therefore wish this institution the very greatest of success."
More information about the work of the Human Rights Hub is available here: https://www.freiheit.org/human-rights-hub-0
Contacts
Sophie EichhornDeputy Press SpokespersonFriedrich Naumann Foundation for Freedom
Reinhardtstraße 12
10117 Berlin
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom